Screener
Odyssey Therapeutics ODTX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Odyssey Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Odyssey Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335822
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable | (313) | 991 |
| Lease liabilities | (2,480) | (1,908) |
| Accrued expenses and other current liabilities | (1,418) | (6,758) |
| Net cash used in operating activities | (75,543) | (72,882) |
| Cash flows from investing activities: | ||
| Maturities of marketable securities | 69,900 | 58,250 |
| Purchases of marketable securities | (246,489) | - |
| Proceeds from sale of property and equipment | 281 | 138 |
Item 1. Financial Statements.
FAQ
- What is Odyssey Therapeutics's operating cash flow?
- Odyssey Therapeutics (ODTX) reported operating cash flow of -$34.51M in Q2 2026.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Odyssey Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude